UnitedHealth Price Target Raised to $337 by BofA After Medicare Advantage Rate Finalization

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock got a meaningful vote of confidence from Bank of America on Tuesday, as analyst Kevin Fischbeck raised the firm’s price target to $337 from $315 following a key Medicare Advantage policy update. BofA keeps a Neutral rating on the shares, so the revised target reflects a materially improved policy backdrop for managed care.

The Centers for Medicare & Medicaid Services finalized Medicare Advantage rates for 2027, delivering a net increase of 2.48% that came in above the high end of the 1% to 2% improvement versus the proposal that the market was expecting. The total dollar impact across the industry amounts to $13 billion, covering 35 million Medicare Advantage enrollees.

The Analyst’s Case

BofA raised price targets across several managed care names, citing higher multiples after CMS finalized Medicare Advantage rates, as the rule provides visibility on 2027 rates. The finalized rate increase exceeded expectations, giving insurers a clearer runway to price products profitably going into next year. That visibility matters for a company like UnitedHealth, which spent much of 2025 absorbing cost trends that outpaced pricing assumptions.

BofA wasn’t alone in revising its managed care outlook. The firm also raised its target on Humana (NYSE:HUM) to $210 from $196 (Neutral), Elevance Health (NYSE:ELV) to $405 from $385 (Neutral), and Molina Healthcare (NYSE:MOH) to $152 from $145 (Underperform).

Company Snapshot

UnitedHealth Group is one of the largest health insurers in the U.S., operating through UnitedHealthcare on the insurance side and Optum Health, Optum Insight, and Optum Rx on the services side. Full-year 2025 revenue came in at $447.57 billion, up 11.81% year over year, though operating income fell 41.26% as the medical care ratio climbed to 88.9%. The company is now deliberately shrinking its membership base, planning to exit 2.3 to 2.8 million members from unprofitable contracts in 2026.

Why the Move Matters Now

UnitedHealth shares are up 8% this morning, but they previously had a rough stretch. The stock is still down 8% year to date and has declined 42% over the past year, with shares currently trading around $305. The CMS rate finalization gives the company a more predictable cost-recovery framework heading into 2027 — exactly the kind of clarity that can stabilize a beaten-down stock. Management’s 2026 adjusted EPS guidance calls for more than $17.75, signaling a recovery from the pressures that defined last year.

The forward P/E ratio sits at roughly 16x, well below the trailing multiple, suggesting the market is already pricing in a meaningful earnings rebound. The analyst consensus average price target stands at $357.81, making BofA’s $337 target one of the more conservative reads on the street.

What It Means for Your Portfolio

If you’re a long-term investor watching UnitedHealth stock, the CMS rate finalization removes one significant overhang. The BofA price target raise reflects improved visibility, not a fundamental turnaround call, and the Neutral rating is a reminder that execution risk remains real. Watch for whether Q1 2026 earnings, expected April 21, show the medical cost ratio continuing to stabilize before drawing stronger conclusions.

The sector-wide nature of BofA’s upgrades signals a policy-driven re-rating, not a company-specific catalyst — meaningful context for anyone weighing managed care exposure in a retirement portfolio right now.